[ Price : $8.95]
FDA is soliciting projects to fund under a new pilot program to enhance regulatory science for biosimilars and interchangeable pro...[ Price : $8.95]
Takeda says it will discontinue manufacturing Natpara (parathyroid hormone) for injection due to manufacturing woes that caused pr...[ Price : $8.95]
FDA tells Inhibrx that there is potential to pursue an accelerated approval for INBRX-101 for treating patients with emphysema due...[ Price : $8.95]
FDA launches a Rare Disease Endpoint Advancement pilot program as called for in the PDUFA 7 reauthorization.[ Price : $8.95]
FDA warns Ocean, NJ-based Flawless Beauty and Skin that it is illegally distributing imported medical devices used in skin care.[ Price : $8.95]
FDA warns Dupo, IL-based Sterling Pharmaceutical Services about CGMP and other violations in its production of finished drugs.[ Price : $8.95]
FDA starts the Split Real Time Application Review pilot program called for in the PDUFA 7 reauthorization.[ Price : $8.95]
The U.S. Supreme Court asks the government to weigh in on Tevas appeal of a court decision in a case involving a so-called skinny ...